¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"depolarizing neuromuscular blocking drug"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® antianginal drug ÇÑ±Û Ç×Çù½ÉÁõÁ¦
¼³¸í   
  Çù½ÉÁõÀº ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°ÔÇϰųª ½ÉÀåÀÌ Ç÷·ù¿¡ ºñÇØ¼­ ¸¹Àº ÀÏÀ» Çϴ °ÍÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Ä¡·áµÉ ¼ö ÀÖ´Ù. ¨ç nitrate°èÅëÀÇ ¾à¹°: Ç÷°üÀ» À̿ϽÃ۴ ÀÛ¿ëÀ» ÇÔÀ¸·Î½á ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù. ¨è Ä®½·Åë·ÎÂ÷´ÜÁ¦(verapamil, nifedipine): ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â CaÀÌ °ü¿©ÇÑ´Ù. Áï CaÀÌ ÀÖ¾î¾ß¸¸ ±ÙÀ°ÀÇ ¼öÃàÀÌ °¡´ÉÇØÁø´Ù. ±×·¯¹Ç·Î CaÀÌ ¼¼Æ÷¼ÓÀ¸·Î µé¾î°¡´Â °ÍÀ» ¾ïÁ¦Çϴ ¾àÁ¦´Â ±ÙÀ°ÀÇ ¼öÃàÀ» ¸·´Â´Ù. ÀÌ ¾àÀº ½ÉÀåÀÇ ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ½ÉÀå ±ÙÀ°ÀÇ ¼öÃàÀ» ¾ïÁ¦Çϸ砽ÉÀåÀÌ °úµµÇϰԠÀÏÇϴ °ÍÀ» ¸·°í, ¶Ç ½ÉÀ嵿¸ÆÀÇ ¼öÃà¿¡ °ü¿©Çϴ ±ÙÀ°¿¡ ÀÛ¿ëÀ» ÇÏ¿© ½ÉÀ嵿¸ÆÀ» À̿ϽÃÄѼ­ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù.
  
  ¨é º£Å¸Â÷´ÜÁ¦(beta-blocker): ½ÅüÀÇ ¿îµ¿·®À̳ª ±âŸÀÇ ¿ä±¸¿¡ ÀÇÇØ¼­ ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇϴ ½Å°æÀº ¹Ù·Î º£Å¸-±³°¨½Å°æÀÌ´Ù. ±³°¨½Å°æ°è¶õ »ç¶÷ÀÌ À§±ÞÇÑ »óȲ¿¡¼­ ÀÛ¿ëÇϴ ÀÚÀ²½Å°æ°èÀÌ´Ù. Áï »ç¶÷ÀÌ ±äÀåÇϰųª ½Î¿ï °æ¿ì¿¡ ÀüÇüÀûÀ¸·Î ±³°¨½Å°æ°è°¡ ÀÛ¿ëÇÑ´Ù. Áï ½ÉÀåÀÌ ¶Ù°Å³ª ¼ÒÈ­°¡ ¾ÊµÇ°Å³ª µ¿°øÀÌ Ä¿Áö´Â °Í µûÀ§°¡ ¹Ù·Î ±³°¨½Å°æ°èÀÇ ¿ªÇÒÀ̶ó°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ ±³°¨½Å°æ°è¿¡¼­ ¸»ÃÊÀå±â¿¡ º¸³»´Â ½Å°æÀÌ ±³°¨½Å°æÀÌ´Ù. ±×·¯¹Ç·Î ½ÉÀå¿¡¼­ ½ÉÀåÀ» ½Åü¿¡ Çʿ信 µû¶ó¼­ ¸¹Àº ÀÏÀ» ÇϰÔÇϴ ½Å°æÀ» Â÷´ÜÇÒ °æ¿ì¿¡´Â Çù½ÉÁõÀ» Ä¡·áÇÒ ¼ö ÀÖ°Ô µÈ´Ù(½ÉÀåÀÇ »ê¼Ò³ª ±âŸ ¿µ¾çºÐÀÇ ¼ö¿ä¸¦ ÁÙÀδÙ).
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • neuromuscular dysfunction
    ½Å°æ±Ù(À°)±â´ÉÀÌ»ó
  • neuromuscular junction
    ½Å°æ±Ù(À°)ÀÌÀ½ºÎ
  • neuromuscular monitoring
    ½Å°æ±Ù(À°)°¨½Ã
  • neuromuscular receptor
    ½Å°æ±Ù(À°)¼ö¿ëü
  • neuromuscular spindle
    ½Å°æ±Ù(À°)¹æÃß
  • neuromuscular synapse
    ½Å°æ±Ù(À°)½Ã³À½º, ½Å°æ±Ù(À°)¿¬Á¢
  • neuromuscular transmission
    ½Å°æ±Ù(À°)Àü´Þ
  • proprioceptive neuromuscular facilitation
    °íÀ¯°¨°¢½Å°æ±ÙÀ°ÃËÁø
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antianxiety drug
    Ç׺ҾÈÁ¦, ºÒ¾ÈÄ¡·áÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticancer drug
    Ç×¾ÏÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antidiabetic drug
    ´ç´¢º´¾à
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    Ç×±Õ¾à
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • psychoactive drug
    Á¤½ÅÀÛ¿ë¾à
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • drug treatment
    ¾à¹°Ä¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • neuromuscular disease
    ½Å°æ±ÙÀ°º´
  • neuromuscular disorder
    ½Å°æ±ÙÀ°Àå¾Ö, ½Å°æ±ÙÀ°Áúȯ
  • neuromuscular dysfunction
    ½Å°æ±ÙÀ°±â´ÉÀå¾Ö
  • neuromuscular junction
    ½Å°æ±ÙÀ°ÀÌÀ½ºÎ
  • neuromuscular monitoring
    ½Å°æ±ÙÀ°°¨½Ã
  • neuromuscular
    ½Å°æ±ÙÀ°-
  • neuromuscular receptor
    ½Å°æ±ÙÀ°¼ö¿ëü
  • neuromuscular spindle
    (¢¡muscle spindle) ±ÙÀ°¹æÃß
  • neuromuscular stimulant
    ½Å°æ±ÙÀ°ÀÚ±ØÁ¦
  • neuromuscular synapse
    ½Å°æ±ÙÀ°¿¬Á¢
  • neuromuscular transmission
    ½Å°æ±ÙÀ°Àü´Þ
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÀ°Á¢ÇÕÀü¼ö¿ëü
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£Ç¥Çö
  • NDA : new drug application
    ½Å¾àÇã°¡½Åû.
  • TDM : therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ ¸ð´ÏÅ͸µ.
  • addiction, drug
    ¸¶¾à»ó½À(ئå·ßÈã§)
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°ÈïºÐ¾à, ¾Æµå·¹³¯¸°ÀÚ±ØÁ¦.
  • adulterated drug
    ¼¯À½Áú¾àǰ.[¿¹¹æ]ºÎÁ¤¾àǰ(ËÓËøËâ̰).
  • allergy, drug
    ¾à¹°¾Ë·¹¸£±â
  • antiallergic agent =a. drug
    Ç׾˷¹¸£±â¾à.
  • antiallergic drug
    Ç׾˷¹¸£±â¾à.
  • antiamebic drug
    Ç׾Ƹ޹پà.
  • antianxiety drug
    Ç׺ҾȾà(ù÷ÝÕäÌå·).
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • neuromuscular disorder
    ½Å°æ±ÙÀ°Áúȯ
  • neuromuscular disorder
    ½Å°æ±ÙÁúȯ(~òðü´).
  • neuromuscular dysfunction
    ½Å°æ±Ù ±â´ÉºÎÀü, ¡­±â´ÉÀå¾Ö
  • neuromuscular junction
    ½Å°æ±ÙÁ¢ÇÕ(ºÎ)(~ïÈùêÝ»).
  • neuromuscular junction
    ½Å°æ±ÙÁ¢ÇÕ(ºÎ)(¡­ÐÉïÈùêÝ»)
  • neuromuscular monitoring
    ½Å°æ±Ù°¨½Ã
  • neuromuscular receptor
    ½Å°æ±Ù¼ö¿ëü
  • neuromuscular spindle
    ½Å°æ±Ù¹æÃß(~Û·õß).
  • neuromuscular spindle
    ½Å°æ±ÙÀ°¹æÃß
  • neuromuscular stimulant
    ½Å°æ±ÙÀÚ±ØÁ¦.
  • neuromuscular synapse
    ½Å°æ±ÙÀ°¿¬Á¢, ½Å°æ±ÙÁ¢ÇÕºÎ.
  • neuromuscular terminal
    ½Å°æ±ÙÀ°Á¾¸»
  • neuromuscular terminal of spindle
    ¹æÃ߽Űæ±ÙÀ°Á¾¸»
  • neuromuscular transmission
    ½Å°æ±Ù(ÈïºÐ)Àü´Þ(~îîÓ¹).
  • neuromuscular transmission
    ½Å°æ±ÙÀü´Þ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DAP data acquisition processor; depolarizing afterpotential; diabetes-associated peptide; diaminopimelic...
DMR depolarizing muscle relaxant; Diploma in Medical Radiology
PDS pain-dysfunction syndrome; paroxysmal depolarizing shift; patient data system; Patient-Doctor Societ...
SDS same day surgery; school dental services; self-rating depression scale; sensory deprivation syndrome...
BA Bachelor of Arts; backache; bacterial agglutination; basilar artery; basion; benzyladenine; best amp...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PIBF Progesterone Induced Blocking Factor
TSBAb Thyroid stimulation blocking antibodies
TSBAb Thyroid stimulation-blocking antibody
BF blocking factor
FNS Functional Neuromuscular Stimulation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • neuromuscular disorder
    ±Ù½Å°æ°è Áúȯ, ±Ù½Å°æ Àå¾Ö, ½Å°æ±Ù Áúȯ
  • neuromuscular function
    ±Ù½Å°æ ±â´É
  • neuromuscular junction
    ½Å°æ±Ù Á¢ÇÕ, ½Å°æ±Ù Á¢ÇÕºÎ
  • neuromuscular protecting mechanism
    ±Ù½Å°æ°èÀÇ º¸È£ ±âÀü
  • neuromuscular reflex activity
    ±Ù½Å°æ ¹Ý»ç Ȱµ¿
  • neuromuscular spindle
    ½Å°æ±Ù ¹æÃß
  • neuromuscular symptom
    ½Å°æ Ç÷°ü Áõ»ó
  • neuromuscular system
    ±Ù½Å°æ°è, ½Å°æ ±ÙÀ°°è
  • neuromuscular unit
    ½Å°æ±Ù ´ÜÀ§
  • receptor blocking agent
    ¼ö¿ëü Â÷´ÜÁ¦
  • sympathetic blocking agent
    ±³°¨½Å°æ ºÀ¼âÁ¦, ±³°¨½Å°æ Â÷´ÜÁ¦
  • addicting drug
    ½À°ü¼º ¾à
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • anesthetic drug
    ¸¶Ãë ¾à
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
adrenergic neuronal blocking agent A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines.
(05 Mar 2000)
alpha-adrenergic blocking agent An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
Synonym: alpha-blocker.
(05 Mar 2000)
alpha blocking The attenuation of the occipital alpha rhythm (8-14 Hz brain waves as seen on an electroencephalogram), produced by opening the eyes or by intense mental concentration.
(05 Mar 2000)
antibodies, blocking Antibodies that inhibit the reaction between antigen and other antibodies or sensitised T-lymphocytes (e.g., antibodies of the IgG class that compete with IgE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumours and prevent destruction of tumour cells by cytotoxic T-lymphocytes have also been called enhancing antibodies.
(12 Dec 1998)
beta-adrenergic blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
beta-adrenergic receptor blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
blocking 1. Obstructing; arresting of passage, conduction, or transmission.
2. In psychoanalysis, a sudden break in free association occurring when a painful subject or repressed complex is touched.
3. Sudden cessation of thoughts and speech, which may indicate the presence of a severe thought disorder or a psychosis.
(05 Mar 2000)
blocking activity The repression or elimination of electrical activity in the brain by the arrival of a sensory stimulus.
(05 Mar 2000)
blocking agent A class of drugs that inhibit (block) a biologic activity or process, such as axonal conduction or transmission, or ions across a cell membrane; frequently called "blockers."
(05 Mar 2000)
blocking antibody An antibody used in a reaction to prevent some other reaction taking place, for example one antibody competing with another for a cell surface receptor.
See: desensitisation.
(18 Nov 1997)
ganglionic blocking agent An agent that impairs the passage of impulses in autonomic ganglia.
(05 Mar 2000)
Rh blocking test A test for nonagglutinating Rh antibodies: an Rh agglutination test is first carried out; if the test for Rh agglutinins is negative, then 1 drop of anti-Rho agglutinating serum of moderate titre is mixed with the patient's serum containing Rh-positive test cells; if after incubating for from 1 to 2 hr at 37°C no agglutination occurs, Rho-blocking antibodies are assumed to be present in the patient's serum.
(05 Mar 2000)
slow channel-blocking agent calcium channel-blocking agent
spermatogenesis-blocking agents Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa.
(12 Dec 1998)
abnormalities, drug-induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mood drug
    ±âºÐ ¾à(ÈïºÐÁ¦,ÁøÁ¤Á¦ µî)
  • prescription drug
    ÀÇ»çÀÇ Ã³¹æÀüÀÌ ÇÊ¿äÇÑ ¾à
  • soft drug
    ¾àÇÑ ¸¶¾à(¸¶¸®È­³ª µûÀ§)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á